Skip to main content
Cipla Ltd. logo

Cipla Ltd. — Investor Relations & Filings

Ticker · CIPLA ISIN · INE059A01026 LEI · 335800KMJJYEDDK82Q34 BSE.NS Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2020-01-28 Regulatory Filings
Country IN India
Listing BSE.NS CIPLA

About Cipla Ltd.

https://www.cipla.com/

Cipla Ltd. is a global pharmaceutical company focused on the development, manufacturing, and marketing of a wide range of generic and branded medicines. The company maintains a diverse portfolio of over 1,500 products across various therapeutic areas, including respiratory, anti-retroviral, urology, cardiology, anti-infective, and central nervous system treatments. It is recognized for its leadership in respiratory care and its historical role in making HIV/AIDS treatment affordable through the introduction of low-cost antiretroviral drugs. Operating with a strong emphasis on research and development, the firm utilizes advanced technology to produce complex generics and drug delivery systems. Its global footprint spans multiple continents, serving healthcare providers and patients in numerous international markets through a robust supply chain and manufacturing infrastructure.

Recent filings

Filing Released Lang Actions
Following the inspection by the United States Food and Drug Administration (USFDA) at the Invagen (US) manufacturing facility from December 2, 2019 to December 6, 2019, the Company has ....
Regulatory Filings Classification · 95% confidence The document text is extremely short (64 characters) and contains no substantive content, financial data, or any indication of report type. It only includes a placeholder for an omitted picture and no other information. Given the lack of content, this cannot be classified as a full report or detailed filing. It is most consistent with a Regulatory Filing (RNS) as a fallback category for miscellaneous or insufficient filings.
2020-01-28 English
Updates
Regulatory Filings Classification · 100% confidence The document text is extremely short (64 characters) and contains no substantive content, only a placeholder for an omitted picture. There is no financial data, no report content, no announcements, or any other information to classify as a specific report type. Given the lack of content, the document cannot be classified as a report or announcement. It fits best as a Regulatory Filing (RNS) which is the fallback category for miscellaneous filings without specific content.
2020-01-28 English
Updates
Regulatory Filings Classification · 95% confidence The document text is extremely short (128 characters) and contains no substantive content, only placeholders for omitted pictures. There is no financial data, no report content, no announcements, or any textual information to classify as a specific report type. Given the lack of content, the document does not fit any specific filing category and defaults to the fallback category Regulatory Filings (RNS).
2020-01-24 English
United States Food and Drug Administration (''USFDA'') conducted a cGMP inspection at our API manufacturing facility in Bommasandra, Bangalore from 20th January, 2020 to 24th January, 2020. ....
Regulatory Filings Classification · 100% confidence The document text is extremely short (128 characters) and contains no substantive content, only placeholders for omitted pictures. There is no financial data, no report content, no announcements, or any textual information to classify as a specific report type. Given the lack of content, the document does not fit any specific filing category and defaults to the fallback category for miscellaneous or non-informative filings, which is Regulatory Filings (RNS).
2020-01-24 English
Updates
Regulatory Filings Classification · 100% confidence The document text contains only placeholders for images and no substantive text or financial data. The true document length is only 181 characters, indicating it is extremely short and contains no report content. There is no indication of any report, announcement, or filing type. Given the lack of content, this document does not fit any specific report category and defaults to the fallback category for miscellaneous filings.
2020-01-22 English
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company wishes to inform you that the United States Food and Drug Administration ....
Regulatory Filings Classification · 90% confidence The document text contains only placeholders for images and no substantive text or financial data. The length is very short (181 characters), and there is no indication of any report content, announcement, or regulatory information. Given the absence of any meaningful content, the document cannot be classified as a report or announcement type. It fits best as a Regulatory Filing (RNS) by default, as a fallback category for miscellaneous filings without clear classification.
2020-01-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.